Uploaded October 2023 | Updated November 2026, 1 day ago
A phase 3 trial shows comparable success rates between ceftobiprole and daptomycin in treating Staphylococcus aureus bacteremia. Ceftobiprole could be a viable alternative treatment, despite slightly higher adverse effects.
State of Health Podcast: open.spotify.com/show/7JWc9FSny48WVhYr0GgBbn
Join this channel to get access to perks:
youtube.com/channel/UCUqgkmGj16aRxmVlHnDdVbw/join
A phase 3 trial shows comparable success rates between ceftobiprole and daptomycin in treating Staphylococcus aureus bacteremia. Ceftobiprole could be a viable alternative treatment, despite slightly higher adverse effects.
State of Health Podcast: open.spotify.com/show/7JWc9FSny48WVhYr0GgBbn
Join this channel to get access to perks:
youtube.com/channel/UCUqgkmGj16aRxmVlHnDdVbw/join










